COVID-19-associated respiratory failure
WikiDoc Resources for COVID-19-associated respiratory failure
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Synonyms and keywords:2019 novel coronavirus disease, COVID19, Wuhan virus, Type 1 respiratory failure, Hypoxemic respiratory failure
The most devastating complication of SARS-CoV-2 is acute hypoxaemic respiratory failure which requires mechanical ventilation. There can be multiple causes that can lead to acute hypoxemic respiratory failure ranging from pulmonary edema, vascular occlusion, ventilation/perfusion mismatch, and hemoglobinopathies. The most important pathology is usually acute respiratory distress syndrome (ARDS) that eventually leads to hypoxemic respiratory failure in patients that are not maintaining oxygen saturation. The difference between COVID related ARDS and the usual ARDS is the injury site which is mainly the respiratory system involving the alveolar epithelial cells. Usually, the clinical symptoms don't correlate with the severity of imaging and laboratory findings. Lung compliance may be normal in some patients. The patients that progress towards acute respiratory failure are usually managed by mechanical intubation with tidal volume target of 6mL/kg PBW.
- In December 2019, an outbreak of coronavirus disease (COVID-19) broke out in Wuhan, China.
- COVID-19 was a clustering pneumonia like illness which affected patients that rapidly developed ARDS.
- ARDS is one of the most important causes of hospital and ICU admission due to COVID.
- Many autopsies studies reported ARDS to be the cause of death in patients dying due to respiratory complications of COVID.
- Respiratory failure can be classified into two types.
- Primarily, COVID-19 associated respiratory failure is type 1 respiratory failure which is actually hypoxemic respiratory failure.
|Hypoxemic Respiratory Failure (Type 1)||Hypoxemic Respiratory Failure (Type 2)|
|PaO2 is lower than 60 mmHg||PaCO2 is greater than 50 mmHg|
|Most common form of respiratory failure||Mostly seen in COPD patients|
||Other Etiologies may include|
- After the infection of the SARS-CoV-2 virus, Type II pneumocytes release inflammatory cytokines that recruit macrophages.
- Macrophages further release cytokines that cause vasodilation and allow more neutrophils and macrophages to come to the site of injury.
- Fluid starts accumulating into the alveolus which leads to dilution of surfactant.
- SARS-CoV-2 propagates within type II cells and releases a large number of viral particles. The type II pneumocytes undergo apoptosis and die. This results in a self-replicating pulmonary toxin as the released viral particles infect type II cells in adjacent units.
- Normally, type II cells are the precursor cells for type I cells.
- This postulated sequence of events has been further supported by the murine model of influenza pneumonia.
- The pathological result of SARS and COVID-19 is diffuse alveolar damage in which there is the development of fibrin hyaline membranes and formation of a few multinucleated giant cells. This aberrant wound healing may lead to further scarring and fibrosis which is more severe than other forms of ARDS.
- Recovery will require a vigorous innate and acquired immune response and epithelial regeneration.
- Elderly individuals are particularly susceptible because of their diminished immune response and inability to regenerate damaged epithelium quickly. Due to reduced mucociliary clearance, it may allow the virus to spread to the gas exchange units of the lung more readily.
- The respiratory failure resulting as a complication of ARDS is due to the result of the acute systemic inflammatory response which is caused by the direct or indirect insults to the lungs.
- In the early exudative stage of ARDS, there occurs the development of diffuse alveolar damage with the destruction of epithelial cells and endothelial cells.
- There are two mechanisms mentioned in the table below which can lead ARDS or any other pathology to respiratory failure in COVID-19:
|V/Q Mismatch||Development of Shunt|
- Airspace filling in acute hypoxemic respiratory failure (AHRF) is due to the following :
Differentiating COVID-19-associated respiratory failure from other Diseases
- Timing of Onset: According to Berlin Criteria of ARDS, the onset must be within 1 week of clinical insult but various reported onsets of COVID-19 related ARDS had mean onset time of 8-12 days from ARDS. It is therefore suggested that there should be caution against the development of ARDS in COVID-19 patients with the course of more than a week.
- Respiratory system compliance: Not all the cases of acute respiratory failure caused by COVID-19 were ARDS. The typical CT findings of the COVID-19 affected patient showed bilateral ground-glass shadow with a peripheral lung distribution. Although there were consolidation and exudation, this was not the typical "ARDS picture".Lung compliance might be relatively normal in some COVID-19-related ARDS patients who met ARDS Berlin criteria which is inconsistent with ARDS caused by other factors. In addition, the lung compliance was relatively high in some COVID-19-related ARDS patients, which was inconsistent with the severity of hypoxemia.
- Severity of Hypoxemia :
|Berlin Criteria Of ARDS leading to respiratory failure||COVID-Related ARDS leading to respiratory failure|
|ARDS is divided into three stages based on oxygenation index (PaO2/FiO2) on PEEP ≥ 5 cmH2O:
||COVID-19-related ARDS was divided into three categories based on oxygenation index (PaO2/FiO2) on PEEP ≥ 5 cmH2O 
Epidemiology and Demographics
- In a sampling of some of the larger epidemiologic studies of patients with COVID-19 to date, rates of invasive mechanical ventilation among patients admitted to ICUs leading to respiratory failure range from 29.1% in one Chinese study to 89.9% in a U.S. study and anywhere from 2.3% of patients admitted to the hospital up to 33.1%.
- The epidemiological data regarding age, gender, and race of patients developing ARDS and subsequent respiratory failure is insufficient.
- Comorbidities and other conditions that have been associated with severe illness and progression of ARDS to subsequent respiratory failure include:
- There is insufficient evidence to recommend routine screening for COVID associated respiratory failure.
Natural History, Complications, and Prognosis
- The development of ARDS and subsequent respiratory failure is a major transition from conservative medical therapy to mechanical ventilation in the management of COVID-19.
- Various case studies show the development of respiratory failure an eventual outcome in patients developing moderate to severe symptoms eventually requiring mechanical ventilation.
- The complications that result from mechanical ventilation which is often required in the patients developing respiratory failure include:
- The mortality from COVID-19 appears driven by the presence of severe ARDS and subsequent respiratory failure is approximately 50 percent (range 12 to 78 percent). 
- Other risk factors associated with death among critically ill patients include the development of severe ARDS and requirement of mechanical ventilation, comorbidities, increased markers of inflammation, worsening lymphopenia,neutrophilia and troponin leak.
Diagnostic Study of Choice
- There are no established criteria for the diagnosis of COVID-19 associated respiratory failure.
- Caution is observed when a patient develops ARDS and oxygen saturation is maintained with HFNC and non-invasive ventilation.
- Respiratory failure is set into play when there is SpO2 sat <90% despite maximal supplemental oxygen.
- Chest X-ray and arterial blood gas measurement is done periodically to check for the development of ARDS.
History and Symptoms
- The patient usually has a history of PCR positive COVID-19 and has already developed symptoms of ARDS which include difficulty in breathing and failure to maintain oxygen saturation on room air.
- The patient may also present with restlessness, anxiety, loss of consciousness, rapid and shallow breathing, racing heart , irregular heartbeats,and profuse sweating.
- Cyanosis can be seen on a general physical exam.
- Altered level of sensorium or consciousness.
- Crackles during chest auscultation which are worse at lung bases.
- Jugular venous distention with high levels of end-expiratory pressure.
- One needs to document two of the three criteria to formally diagnose acute respiratory failure: pO2 less than 60 mm Hg (or room air oxygen saturation less than or equal to 90%), pCO2 greater than 50 mm Hg with pH less than 7.35, and signs/symptoms of respiratory distress.
Tests of Oxygenation
- PaO2/FiO2 ratio (PF ratio)
- Normal is 500
- ARDS is < 200
- This measure is easier to calculate.
- Comparative studies suggest it correlates better with pulmonary shunts than does the A-a gradient.
- Alveolar-arterial oxygen (A-a) gradient (alveolar-arterial oxygen difference - AVO2D)
- Normal is < 10 mm Hg
- Although, it is difficult to calculate A-a gradient and also it relies on the respiratory quotient being constant in the prediction of alveolar CO2 but it still accounts for changes in the respiration as measured by the partial pressure of carbon dioxide.
- When compared to the PF ratio, the A-a gradient is found to correlate less well with pulmonary shunting.
- Particular lab findings associated with a worse prognosis include:
- There are no ECG findings associated with COVID associated respiratory failure.
Echocardiography or Ultrasound
- There are no echocardiography/ultrasound findings associated with COVID associated respiratory failure.
- A chest x-ray is done to periodically categorize the severity of ARDS along with arterial blood gases.
- Findings on x-ray suggestive of acute respiratory distress include:
- There are no CT scan findings associated with respiratory failure due to COVID-19.
- However, a CT scan may be helpful in the diagnosis of complications of coronavirus which include the Ground glass (GGO) pattern which is a common finding in COVID-19 patients with following characteristics:
- Multifocal (GGO presents as a unifocal lesion in the early phase of the disease).
- Most commonly located in the inferior lobe of the right lung.
- There are no MRI findings associated with respiratory failure due to COVID-19.
Other Imaging Findings
- There are no other imaging findings associated with respiratory failure due to COVID-19.
Other Diagnostic Studies
- There are no other diagnostic studies associated with respiratory failure due to COVID-19.
- There is no treatment for respiratory failure due to COVID-19; the mainstay of therapy is supportive care and mechanical ventilation.
Indications of Tracheal intubation and Mechanical Ventilation
- Following is the list of indications for tracheal intubation and mechanical ventilation in COVID-19 associated respiratory failure:
- Signs of respiratory distress such as:
- Accessory muscle use
- Paradoxical abdominal breathing)
- Rapid progression of the disease
- SpO2 sat <90% despite maximal supplemental oxygen
- Arterial pH <7.3 with PaCO2 >50
- Patient requiring >40 L/minute HFNC and FiO2 >0.6
- Hemodynamic instability; multiorgan failure
- Signs of respiratory distress such as:
- Following is the list of ventilator settings required in COVID-19 associated respiratory failure:
|Low Tidal Volume Ventilation is recommended|
Management of Complications
- Daily laboratory studies should be done to monitor for complications including acute kidney injury, pericarditis, sudden cardiac death and superinfection.
- Complete blood count with differential, chemistries, liver function and coagulation studies, arterial blood gases, ferritin level, D-dimer level, and lactate dehydrogenase are usually performed every day.
- It has been recommended in RECOVERY Trial that for patients requiring mechanical ventilation or those requiring oxygen should be given low dose dexamethasone (6mg daily for 10 days) for ICU patients.
- It has been shown to reduce the mortality rate by 1/3 rd in mechanically ventilated patients.
- The best way to prevent being infected by COVID-19 is to avoid being exposed to this virus by adopting the following practices for infection control:
- Often wash hands with soap and water for at least 20 seconds.
- Use an alcohol-based hand sanitizer containing at least 60% alcohol in case soap and water are not available.
- Avoid touching the eyes, nose, and mouth without washing hands.
- Avoid being in close contact with people sick with COVID-19 infection.
- Stay home while being symptomatic to prevent spread to others.
- Cover mouth while coughing or sneezing with a tissue paper, and then throw the tissue in the trash.
- Clean and disinfect the objects and surfaces which are touched frequently.
- There is currently no vaccine available to prevent COVID-19.
- The secondary prevention measures of Coronavirus disease 2019 (COVID-19) constitute protective measures to make sure that an infected individual does not transfer the disease to others by maintaining self-isolation at home or designated quarantine facilities.
- Li, Xu; Ma, Xiaochun (2020-05-06). "Acute respiratory failure in COVID-19: is it "typical" ARDS?". Critical Care. Springer Science and Business Media LLC. 24 (1). doi:10.1186/s13054-020-02911-9. ISSN 1364-8535.
- Chen, Yun; Guo, Yao; Pan, Yihang; Zhao, Zhizhuang Joe (2020). "Structure analysis of the receptor binding of 2019-nCoV". Biochemical and Biophysical Research Communications. Elsevier BV. 525 (1): 135–140. doi:10.1016/j.bbrc.2020.02.071. ISSN 0006-291X.
- Mason, Robert J. (2020). "Pathogenesis of COVID-19 from a cell biology perspective". European Respiratory Journal. European Respiratory Society (ERS). 55 (4): 2000607. doi:10.1183/13993003.00607-2020. ISSN 0903-1936.
- Zucker, AR (1988). "Therapeutic strategies for acute hypoxemic respiratory failure". Critical care clinics. 4 (4): 813–30. ISSN 0749-0704. PMID 3052710.
- "Acute Respiratory Distress Syndrome". JAMA. American Medical Association (AMA). 307 (23). 2012-06-20. doi:10.1001/jama.2012.5669. ISSN 0098-7484.
- Phua, Jason; Weng, Li; Ling, Lowell; Egi, Moritoki; Lim, Chae-Man; Divatia, Jigeeshu Vasishtha; Shrestha, Babu Raja; Arabi, Yaseen M; Ng, Jensen; Gomersall, Charles D; Nishimura, Masaji; Koh, Younsuck; Du, Bin (2020). "Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations". The Lancet Respiratory Medicine. Elsevier BV. 8 (5): 506–517. doi:10.1016/s2213-2600(20)30161-2. ISSN 2213-2600.
- "Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology". American Journal of Respiratory and Critical Care Medicine. 2020-07-01. Retrieved 2020-07-02.
- Liu, Kui; Fang, Yuan-Yuan; Deng, Yan; Liu, Wei; Wang, Mei-Fang; Ma, Jing-Ping; Xiao, Wei; Wang, Ying-Nan; Zhong, Min-Hua; Li, Cheng-Hong; Li, Guang-Cai; Liu, Hui-Guo (2020-05-05). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese medical journal. Ovid Technologies (Wolters Kluwer Health). 133 (9): 1025–1031. doi:10.1097/cm9.0000000000000744. ISSN 0366-6999. PMC 7147277 Check
|pmc=value (help). PMID 32044814 Check
- Arentz, Matt; Yim, Eric; Klaff, Lindy; Lokhandwala, Sharukh; Riedo, Francis X.; Chong, Maria; Lee, Melissa (2020-04-28). "Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State". JAMA. American Medical Association (AMA). 323 (16): 1612. doi:10.1001/jama.2020.4326. ISSN 0098-7484. PMC 7082763 Check
|pmc=value (help). PMID 32191259 Check
- Wu, Chaomin; Chen, Xiaoyan; Cai, Yanping; Xia, Jia’an; Zhou, Xing; Xu, Sha; Huang, Hanping; Zhang, Li; Zhou, Xia; Du, Chunling; Zhang, Yuye; Song, Juan; Wang, Sijiao; Chao, Yencheng; Yang, Zeyong; Xu, Jie; Zhou, Xin; Chen, Dechang; Xiong, Weining; Xu, Lei; Zhou, Feng; Jiang, Jinjun; Bai, Chunxue; Zheng, Junhua; Song, Yuanlin (2020-03-13). "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China". JAMA internal medicine. American Medical Association (AMA). doi:10.1001/jamainternmed.2020.0994. ISSN 2168-6106. PMC 7070509 Check
|pmc=value (help). PMID 32167524 Check
- Chen, Nanshan; Zhou, Min; Dong, Xuan; Qu, Jieming; Gong, Fengyun; Han, Yang; Qiu, Yang; Wang, Jingli; Liu, Ying; Wei, Yuan; Xia, Jia'an; Yu, Ting; Zhang, Xinxin; Zhang, Li (2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". The Lancet. Elsevier BV. 395 (10223): 507–513. doi:10.1016/s0140-6736(20)30211-7. ISSN 0140-6736.
- Covelli HD, Nessan VJ, Tuttle WK (1983). "Oxygen derived variables in acute respiratory failure". Crit. Care Med. 11 (8): 646–9. PMID 6409506.
- El-Khatib MF, Jamaleddine GW (2004). "A new oxygenation index for reflecting intrapulmonary shunting in patients undergoing open-heart surgery". Chest. 125 (2): 592–6. PMID 14769743.
- Cane RD, Shapiro BA, Templin R, Walther K (1988). "Unreliability of oxygen tension-based indices in reflecting intrapulmonary shunting in critically ill patients". Crit. Care Med. 16 (12): 1243–5. PMID 3191742.
- Alanazi, Abdullah (2015). "Intubations and airway management: An overview of Hassles through third millennium". Journal of Emergencies, Trauma, and Shock. Medknow. 8 (2): 99. doi:10.4103/0974-2700.145401. ISSN 0974-2700.
- "About". NHLBI ARDS Network (in italiano). Retrieved 2020-07-02.
- RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL; et al. (2020). "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report". N Engl J Med. doi:10.1056/NEJMoa2021436. PMID 32678530 Check
- "Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19". RECOVERY Trial. 2020-06-16. Retrieved 2020-07-02.